Biomatics Capital

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company that focuses on the design and development of devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin issues by offering non-surgical solutions to remove sagging skin without causing scarring. Its innovative devices provide aesthetic practitioners with advanced tools to enhance skin appearance, thereby improving patient outcomes in the field of aesthetic medicine.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

BlueTalon, Inc. specializes in data collaboration and unification technologies, offering solutions that enhance data-centric security for big data environments. The company's key products include the Control Your Data solution, the BlueTalon Virtual Database, and the BlueTalon Policy Engine, which collectively facilitate secure access and management of data across various platforms, including Hadoop, Spark, and SQL-based systems. These tools enable organizations to enforce precise user access controls, ensuring compliance and reducing security risks. BlueTalon's services allow users to access corporate data seamlessly across different departments and locations without the need for extensive modifications to existing databases or applications. Founded in 2013 and headquartered in Redwood City, California, BlueTalon has gained recognition for its innovative approach to data security, earning accolades such as being named a Gartner Cool Vendor in 2016. As of 2019, BlueTalon operates as a subsidiary of Microsoft Corporation, serving a wide range of clients, including Fortune 100 companies, that seek to enhance their visibility and control over sensitive data.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.